Alvotech (ALVO) Aktienanalyse

Unternehmensübersicht

Alvotech operates as a specialized developer and manufacturer of biosimilar medicines intended for patients globally across various therapeutic areas, including autoimmune disorders, eye conditions, bone disorders, and cancer. The company functions within the healthcare sector, specifically classified under the industry of drug manufacturers specializing in specialty and generic products, which positions it as a provider of lower-cost alternatives to originator biologics. According to the latest available data, the company holds a market capitalization of $969.08 million and reported annual revenue (TTM) of $588.90 million. Although the specific employee count is not disclosed in the current financial records, the revenue figure of approximately $589 million indicates a mid-to-large scale operation within the competitive biosimilar landscape. This valuation suggests the company possesses a significant market presence while maintaining a profile that balances established revenue streams with the capital-intensive nature of pharmaceutical development. The market cap relative to its revenue base reflects investor confidence in its pipeline, particularly its lead program AVT02, which focuses on high-concentration formulations, while the absence of publicly reported headcount data requires reliance on revenue metrics to gauge operational scale.

Finanzielle Gesundheit

The financial performance of Alvotech is characterized by a trailing twelve-month revenue of $588.90 million, a net income of $27.92 million, and an EBITDA of $115.76 million. The substantial gap between the $588.90 million in revenue and the $27.92 million in net income reveals a distinct cost structure where operating expenses, including research and development, significantly impact the bottom line before tax adjustments. The company generated free cash flow of $12.34 million, a metric that indicates positive operational cash generation despite high capital expenditure requirements typical in the biosimilar sector. This positive free cash flow provides the company with essential financial flexibility to fund ongoing clinical trials, manufacturing expansions, or strategic acquisitions without immediate reliance on external financing. Profitability analysis shows a gross margin of 60.4%, an operating margin of 30.9%, and a profit margin of 4.7%, indicating that while the company retains a healthy portion of sales revenue after direct costs, significant operating expenses reduce the final profit to a single-digit percentage. The balance sheet presents a complex picture with cash reserves of $172.36 million against total debt of $1.45 billion, while the debt-to-equity ratio is listed as N/A due to negative equity implications often seen in growth-stage biotechs. The current ratio stands at 1.89, which signals a conservative approach to short-term liquidity management, ensuring the company can comfortably meet its obligations due within a year. Return on equity is marked as N/A, likely due to the negative book value reflected in the price-to-book ratio, whereas the return on assets is 3.6%, suggesting that the asset base is generating a modest but positive return on investment.

Bewertungsanalyse

Valuation metrics for Alvotech indicate a trailing P/E ratio of 31.10 and a forward P/E of 10.29, a sharp divergence that implies the market expects a significant acceleration in earnings growth or a substantial improvement in profitability in the coming fiscal periods. The price-to-book ratio is recorded at -3.41, a negative figure that indicates the company's market value is trading below its book value, a phenomenon often observed in biotechnology firms with heavy intangible assets or negative shareholder equity. Alternative valuation measures such as the price-to-sales ratio of 1.65 and the enterprise value-to-EBITDA multiple of 19.41 provide context by showing that the company is valued at roughly 1.65 times its revenue, which is a premium for a specialty drug manufacturer but potentially justified by the high-margin nature of its biosimilar portfolio. The stock has exhibited notable volatility, trading between a 52-week high of $11.85 and a 52-week low of $3.10. Without the current price explicitly listed in the source text to calculate the exact percentage, the trading range demonstrates a wide band of $8.75, highlighting the speculative nature of the investment where the current price could be significantly below the 52-week high depending on market sentiment. The beta coefficient is 0.18, which indicates that the stock's price volatility is substantially lower than that of the broader market, suggesting a defensive characteristic or low correlation with general market movements.

Growth & Income

Revenue growth over the last year stands at 10.1%, while earnings growth is listed as N/A, indicating that the company has not yet achieved consistent positive year-over-year earnings growth sufficient for standard reporting. The absence of earnings growth data relative to the positive revenue expansion suggests that cost pressures or one-time expenses are currently outpacing top-line growth, which is a common phase for companies transitioning from clinical development to commercialization. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all generated earnings are reinvested into research, development, and manufacturing capacity rather than distributed to shareholders. This reinvestment strategy aligns with the growth profile of a specialty drug manufacturer that prioritizes expanding its product portfolio and advancing programs like AVT02 over providing immediate income returns. Consequently, the overall growth and income profile of Alvotech is defined by capital appreciation potential driven by revenue expansion and future profitability milestones, rather than current yield or stable earnings growth.